2 and would not demonstrate differential inhibition of either moiety. Within the range of the progestogen dosage in oral contraceptive tablets it appears that the cestrogen plays the dominant role in suppressing ovulation. Clinical trials conducted in Birmingham (Eckstein et al. 1961) and Slough (Pullen 1962) showed that the dose of oestrogen becomes critical as the progestogen component is reduced. The tablets contained norethynodrel 2 5 mg but the mestranol content was 0 05 mg and 0-I mg respectively. The failure rate was 29 % in Birmingham but only 1 % in Slough. Goldzieher et al. (1963) secured effective contraception by administering cestrogen alone on the 5th -19th days of the cycle followed by cestrogen and progestogen on the 20th-24th days. The dose of mestranol was only 0-08 mg daily, less than that contained in any commercial tablet except the original form of Conovid which includes a large, compensatory, dose of 19-norsteroid. The progestogen was the 17-hydroxyprogesterone derivative, chlormadinone, 2 mg daily. The failure rate in 938 women during 6,314 cycles was less than one per 100 woman-years which accords with the best results of simultaneous, as opposed to sequential, medication. The oestrogen component of oral contraceptives may mimic the effect of the successful graafian follicle which outstrips and suppresses other aspirants during the normal menstrual cycle.
The progestogen is relegated to the role of controlling the endometrium in respect of breakthrough and withdrawal bleeding and of avoiding endometrial hyperplasia. Records of uterine bleeding during clinical trials on two trade preparations containing ethinyl oestradiol in identical amount but different doses of norethisterone acetate lend support to this hypothesis (Mears 1963, personal communication) . For the patient's convenience intermenstrual bleeding should be eliminated; for her peace of mind withdrawal bleeding must occur and simulate normal menstruation. These requirements cannot be satisfied consistently by the present unphysiological practice of administering progestogens from the 5th day of the cycle. To avoid intermenstrual bleeding during early months the dose of 19-norsteroid must exceed the long-term optimum and this can lead to endometrial regression and amenorrhcea after several cycles. Sequential medication gives an endometrium histologically similar to the normal premenstrual mucosa and subsequent withdrawal bleeding repeatedly resembles a normal menstrual period.
Oral contraception of this type is more effective than physical or chemical methods and its future seems assured unless deleterious long-term sequelh are encountered. New steroid analogues with less immediate side-effects and modified dosage patterns can be anticipated. To avoid the 26and 27-day cycles inherent in the present 20-day regime treatment should be extended to 21 or 22 days. The provision of blank tablets for the remaining days in the cycle would lessen the risk of patient error. If the simultaneous treatment pattern persists, less progestogen could be advised after the first three months to avoid disquieting amenorrhcea and 1 7-hydroxyprogesterone derivatives. may well replace the 19norsteroids. However, the more physiological sequential regime should supersede the present simultaneous dosage scheme and incidentally give cestrogens die acknowledgment of their role in inhibiting ovulation.
Dr Eleanor Mears

(London)
Clinical Experience in the Use of Oral Contraceptives
There is no question that a progestogen/oestrogen mixture, used in the familiar 5th-24th day regime for oral contraception, is the most efficient method of birth control we have ever had. A comparison of the efficiency of all methods of birth control, the failure rate being calculated as the number of pregnancies per 100 woman-years, and including patient as well as method failure, shows that the only other contraceptive method which approaches the Pincus pill in efficiency is the new plastic intrauterine device which is just beginning to be used in clinical trials in this country.
The method of administration of oral contraception allows for an occasional failure in tablet taking without consequent pregnancy. It is essential that the first tablet should be taken on day 5 of the first cycle, perhaps even earlier in the case of a woman with cycles of less than 24 days.
Section ofObstetrics and Gynwcology
In trials in this country no patient who has taken the tablets as instructed, except for missing one pill in any one cycle, has become pregnant (Brit. med.J. 1963).
The method seems to be a highly acceptable one, particularly to fertile couples who dislike mechanical methods and, contrary to expectations, for problem-family women who are normally quite unreliable over contraceptive measures (Peberdy 1962 , personal communication, Rice-Wray et al. 1963 ). This underlines the fact that patients are more painstaking if they find the method acceptable.
Present oral contraceptives are a mixture of one of seven progestogens with owe of two aestrogens. It would be possible to use progestogens with built-in cestrogenic activity by themselves (Group 2, Klopper classification, 1962) , but these would have to be used in large doses. Those progestogens which have no cestrogenic activity require the addition of aestrogen to support the endometrium and to give better cycle control. The dose of progestogen can be reduced when aestrogen is included so that this combined tablet reduces the cost as well as increasing the efficiency and lowers the incidence of side-effects.
In the beginning the optimal combination of these two ingredients may take some time to determine. The most important factor governing the choice of dosage is cycle control-that is, the proportion. of breakthrough bleeding. So far, seven oral contraceptive tablets have been approved for use in Family Planning Association clinics as a result of trials by the Council for the Investigation of Fertility Control (CIFC); these are Conovid, Conovid-E, Anovlar, Volidan, Lyndiol, Ortho-Novin and SC-1800 2 mg (Table 1 ) . Table I Physicians all over the world have been wary of using these potent hormones for this social purpose. In this country we watched with interest what was happening in Puerto Rico and elsewhere for some four years before we felt justified in commencing trials. By the time the first oral contraceptives became available on prescription in this country, two and a half years ago, they had been in use for six years in Puerto Rico. So far it can be said with confidence, after much careful investigation, that no harmful effects have been shown to occur, despite some alarms.
These products are responsible for a number of changes and alterations but, as with all new drugs, such changes have to be assessed. For example, there are marked changes in the endometrium.
[A summary of the endometrium during the normal menstrual cycle was given and these changes discussed before slides of the endometrium of patients who have been on oral contraceptives were shown.] On the 7th day of medication the glands are small and straight with basal vacuoles and stromal oedema already beginningnormally typical of the postovulatory phase. Biopsy on the 17th day shows abundant fibrillary stroma with widely separate, inactive, small, nonconvoluted glands; on or after the 23rd day there is marked stromal cedema and a predecidual effect. There are minor variations in the endometrial picture on the different progestogens (Jackson 1963 ) and they are paralleled by the amount of decrease of menstrual loss which is also a feature of most of these oral contraceptives. We have not yet been able to find any change in the endometrial picture to account for those patients in whomi breakthrough bleeding or amenorrhoea occurs.
Despite these very marked changes, the endometrium returns to normal as soon as medication Effect of approved oral contraception tablets on menstrual cycle 
is discontinued. There is no evidence at present to indicate that different durations of medication make any difference to the speed of recovery of the endometrium (Bockner 1963 ). The first cycle, even after prolonged medication, is usually normal and a higher proportion of patients become pregnant in the first cycle after medication than would normally be expected (Goldzieher et al. 1962) . In CIFC trials we have had 107 patients withdrawing to become pregnant, 88 % of whom conceived within four months.
Vaginal Cytology
These changes in the endometrium are paralleled by changes in the vaginal cytology. There is a depression of the cornification index to produce a hypotrophia resembling that of the menopausea pseudopregnancy effect. Deep layer cells are present and these are never evident in normal women during the childbearing period, except during pregnancy.
Hormonal Balance
These oral contraceptives also produce alteration in the hormonal balance. Hormone assay studies have been undertaken both during and immediately following treatment in women who have previously received oral contraceptive therapy for many months ). Fig 1 shows the estimations of gonadotrophins, pregnanediol, cestriol, cestrone and mstradiol during the last cycle of treatment and the first 2 cycles after treatment was stopped. It is evident from these that gonadotrophin output, as measured by gonadotrophin assays in urine, was not inhibited, though ovarian activity and ovulation were suppressed. This suggests that these agents are capable of producing their effects by direct action on the ovary rather than through the pituitary. Following withdrawal of medication, all subjects showed a rise in pregnanediol output in the luteal phase, indicating that ovulation and a recovery of the output of aestriol, aestrone and oestradiol had occurred (Fig 1) .
Sequential Therapy
One of the more recent variants of this type of therapy has been the sequential regime, using only an oestrogen for fifteen days, followed by a combined tablet of aestrogen plus progestogen for a further five days. This routine has certain advantagesit is cheaper to produce, it produces a more normal endometrium and cervical mucus and, theoretically, seems more physiological. We have 100 patients on the 15+5 routine and the results are shown in Table 2 . As would be expected, there is practically no breast discomfort and a number of patients have an increased . The endometrium shows a marked cestrogenic effect to begin with and this is reduced when the progestogen is added. Thus, in the first week of therapy, the glands are large and plentiful and vary from straight to moderately tortuous. The lining epithelium is tall columnar with oval nuclei arranged in a markedly disordered fashion. There are frequent mitoses. The stromal cells are widely separated by the oedema. Capillaries and sinusoids in most sections are prominent. Over the next six days there is pseudo-stratification of the epithelium and subnuclear vacuoles become apparent although the progestogen has not yet been added. In the last-five days with the combined treatment, intra-epithelial vacuoles are conspicuous in most glands and there is some secretion in the lumen but the endometrium is by no means normal for this stage.
We are also studying other varieties of sequential therapy, e.g. an 11/10-day regime with different doses of both cestrogens and other progestogens.
Clinical Findings
Larger doses of these same progestogen/cestrogen compounds used for gynxcological purposes have been shown to cause enlargement of the uterus and of fibroids, pelvic congestion and swelling of the thyroid, &c. However, at oral contraceptive doses as used in this country, there have been no signs of any of these phenomena. Indeed, while some patients experience early side-effects, many more are delighted to find that they are relieved of many side-effects of the so-called 'normal' menstrual cyclee.g. premenstrual tension, dysmenorrhcea, migraine, breast discomfort. It is my experience that treatment of gynaecologica,l conditions such as functional uterine bleeding, dysmenorrhmea, premenstrual tension, irregular menstruation and even endometriosis, which call for progestogen therapy, is effected equally well with,-the oral contraceptive regime at a smaller dosage and with fewer side-effects.
Mr Wilfrid G Mills (Birmingham)
The Difficulties and Dangers of Oral Contraception Development of oral contraception has been rapid and there has been great co-operation from the pharmaceutical industry. Failures have been few and complications have seldom proved serious. However, there is a growing realization that these cestrogenic and progestational drugs have constitutional effects upon various systems of the body and that trouble may only become evident after prolonged treatment. An account of the difficulties and dangers inherent in the use of these drugs divides naturally into those immediate complications that have in fact been encountered and the more remote contingencies that at present remain speculative.
The rate of unplanned pregnancies has been commendably low and approximates to one pregnancy per 100 woman-years. Pincus (1961) gives the figure as 1 *2 % for 7,000 cycles on Conovid, while gives an almost identical figure of 11 pregnancies in 14,412 cycles among women taking part in the trials of 7 different compounds. This figure, though incomparably better than those of 14 and 12 quoted by Venning (1961) for the male condom and female diaphragm, is still sufficiently substantial to make it worthy of analysis. Accordingly those failures that have come-to our notice in Birmingham since trials of oral contraceptives began in 1960 are discussed below.
